Professional Media briefs: March 2014

Share this article:

New rules are in place for the open access resource PLOS. As of March 1 the journal is requiring all writers provide data. Academic Editor-in-Chief Jonathan Eisen (pictured) and Associate Editor Emma Ganley noted in the PLOS blog that they realize this new policy could drive away authors and that they are OK with that. Eisen and Ganley say this is the direction that funders are going in. “It's time to start ensuring that there are better lab, university and institution practices for the storage and archiving of pertinent data,” they write.

UK GPs are more likely to use search engines than pharmaceutical industry websites to find information. PMLiVE reported that the preference—which showed industry sites came after medical education materials, but before ­social media sites—came from the 2013 National Medical Readership Survey.

Elsevier is giving unpublished work a home. The publisher said in a statement that the goal of the open access MethodsX journal is to give “researchers public credit and citations,” for records that explain how they tweak methods to fit research settings, an effort that the publisher says takes up around 80% of a researcher's time.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?